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The evaluation of 3DRT and IMRT tech-
niques in postoperative radiotherapy for 
thyroid medullary carcinoma
Dorota GABRYŚ1, Iwona WESOŁOWSKA2, Rafał SUWIŃSKI1
SUMMARY
BACKGROUND: Radical surgical excision is the treatment of choice in all medullary thyroid carcino-
mas. External beam radiotherapy for medullary thyroid carcinoma is necessary in advanced cases. 
Unfortunately, a large volume of the head and neck region which has to be irradiated is close to criti-
cal structures such as the spinal cord, larynx, and parotid glands, which creates a challenge during 
radiotherapy planning. 
AIM: The aim of the study is to compare IMRT and 3D plans of patients diagnosed with medullary 
thyroid carcinoma in terms of CTV coverage and normal tissue sparing.
MATERIALS AND METHODS: A 46-year-old woman with medullary thyroid carcinoma, stage pT4a N1b 
M0, underwent radical resection, followed by adjuvant radiotherapy to a total dose 60 Gy to the clini-
cal target volume (CTV). Three plans were generated to irradiate the thyroid bed and regional lymph 
nodes. Two intensity-modulated radiation therapy (IMRT) and three-dimensional conformal radiation 
therapy (3DRT) plans were compared in terms of CTV coverage and organ at risk sparing. 
RESULTS: Using the IMRT plans we achieved more homogeneous dose distribution with higher mini-
mal dose and lower maximal dose in the target volume compared to 3DRT technique. Furthermore, 
mean and maximal dose to critical structures were lower when IMRT was applied compared to 3DRT. 
CONCLUSIONS: IMRT results in improved dose distribution within CTV compared to 3DRT. With the 
IMRT plan it is also possible to reduce the dose to the organ at risk, especially the larynx, salivary 
glands and spinal cord.
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BACKGROUND
Five percent of thyroid malignancies are med-
ullary carcinomas, which arise from parafol-
licular C cells. They are known to have rela-
tively poor prognosis among thyroid cancer 
patients, and their survival rate is 80% [1–3]. 
The standard management is surgery, com-
prising a total thyroidectomy and central node 
dissection if the lymph nodes are thought to 
be involved. Selective lymph node dissection 
might be necessary if further lymph nodes are 
thought to be involved [4–6]. Radiotherapy is 
recommended in completely resected disease 
or as an adjuvant treatment in patients with 
lymph node metastases, when calcitonin lev-
el is high and there is no evidence of distant 
metastases [7, 8]. Radioisotope therapy, che-
motherapy and other pharmacological treat-
ments are delivered only individually in small 
groups of patients. 
In thyroid cancer the dose to a volume at 
risk for microscopic disease is limited by the 
tolerance of critical structures such as spinal 
cord, salivary glands and larynx [3, 9]. It is 
diffi cult to deliver high, therapeutic doses of 
radiation to the thyroid gland or tumour bed 
and its multiple lymphatic draining (up to-
ward the base of the skull and down to the up-
per mediastinum) without causing signifi cant 
toxicity [9]. 
Recently, intensity-modulated radiation 
therapy (IMRT) has been implemented in 
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therapy for head and neck patients [10, 11]. 
Theoretically IMRT creates a possibility to 
achieve better dose distribution by increasing 
dose to the target volume and simultaneously 
decreasing dose to the organ at risk. IMRT 
has been extensively investigated for many 
sites within the head and neck, but studies 
on IMRT in thyroid cancer are scarce. This 
creates the rationale for the present study [3, 
12–16]. 
AIM
The aim of the study is to compare IMRT and 
3D plans of patients diagnosed with medullary 
thyroid carcinoma in terms of CTV coverage 
and normal tissue sparing. 
MATERIAL AND METHODS
A 46-year-old woman was diagnosed with 
medullary thyroid carcinoma. Clinical exami-
nation and all diagnostic procedures such as 
computed tomography, X-ray and ultrasound 
revealed enlarged thyroid with multiple tu-
mours and enlarged bilateral cervical lymph 
nodes. Radical thyroid excisions with excision 
of cervical lymph nodes were performed. The 
histopathological stage was pT4a N1b M0 due 
to extracapsular and tracheal invasion, size 
of tumour 6 x 5 x 3 cm, and 5 cervical lymph 
node metastases. Postoperative calcitonin lev-
el was 510.5 pg/ml. There was no evidence of 
distant metastases. Therefore, the patient was 
referred to the radiotherapy department for 
further treatment. 
The patient was immobilized with a ther-
moplastic mask, and planning CT scan of 
neck and upper thorax was performed. Clini-
cal target volume (CTV) based on CT as well 
as organs at risk in the head and neck region 
were delineated. CTV consisted of the tumour 
bed with margins in all directions and cervi-
cal, retropharyngeal and upper mediastinal 
lymph nodes. Supraclavicular nodes were de-
lineated and denoted as CTV2. A 5 mm mar-
gin was added to CTV and CTV2 to create 
PTV. The target and critical structures were 
defi ned and contoured for the CadPlan-Helios 
treatment planning system. 
Two intensity modulated plans (IMRT) 
were prepared. The fi rst was arranged using 
5-fi eld technique and 6-MV photon beam (5-
fi eld IMRT), and the second using 9-fi eld tech-
nique and 6-MV photon beam (9-fi eld IMRT). 
A 3-dimensional radiotherapy plan (3DRT) 
was also created. A 3DRT plan comprised 
two parts. The fi rst part was arranged using 
3-fi eld technique and 6-MV photon beam; the 
prescribed dose to the CTV and CTV2 was 44 
Gy. The second part involved the use of 4-fi eld 
technique and 6-MV photon beam combined 
with 2 fi elds and 9 MeV electron beams; the 
prescribed dose to the CTV and CTV2 was 
16 Gy. For all plans dose volume histograms, 
minimum, maximum and mean doses were 
calculated (Table 1). CTV and CTV2 were ir-
radiated to a total dose of 60 Gy in 2 Gy per 
fraction per day, over 6 weeks using a Varian 
Clinac 2300 accelerator. Toxicity was moni-
tored weekly during radiotherapy. 
RESULTS
In our study better dose distribution in CTV 
and CTV2 was achieved with IMRT technique 
than with 3DRT technique. Transversal, medi-
an and coronal dose distribution for complete 
3DRT technique is shown in Figure 1 a, c, e 
and for IMRT technique is shown in Figure 1 
b, d, f. All mean doses to the CTV, CTV2 and 
critical structures with minimum and maxi-
mum are shown in Table 1. 
The mean CTV dose was similar in all tech-
niques (9-fi eld IMRT - 59.8 Gy, 5-fi eld IMRT 
- 60.2 Gy vs 3DRT - 60.3 Gy). However, using 
IMRT technique higher minimum and lower 
maximum dose was delivered compared to 
3DRT technique (Table 1). In supraclavicu-
lar nodes (CTV2) mean dose distribution was 
more homogeneous in IMRT (60.3 Gy, 60.8 Gy 
vs 57.6 Gy); furthermore, higher minimum and 
lower maximum was achieved with both IMRT 
techniques compared to 3DRT (Table 1). 
Most profi table in terms of critical struc-
tures sparing were parotid glands and larynx. 
The difference between 9-fi eld IMRT and 
3DRT in mean dose to the larynx was 6.4 Gy. 
Also lower minimum (43.1 Gy vs 59.1 Gy) and 
maximum larynx dose (60.8 Gy vs 63.2 Gy) 
was achieved with 9-fi eld IMTR compared to 
3DRT. The biggest difference in mean dose 
to the organ at risk between these two tech-
niques was found in the left parotid (13.9 Gy); 
for the right parotid the difference in mean 
dose was smaller (9 Gy). Maximum dose to the 
left and right parotid did not differ between 
IMRT and 3DRT, since part of the parotids 
is located close to the CTV. In contrast, both 
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minimum parotid doses were much lower in 
9-fi eld IMRT (Table 1). 
The spinal cord was irradiated to tolerance 
by all three techniques. With 9-fi eld IMRT we 
were able to decrease maximum spinal cord 
dose by 2.6 Gy. Mean and minimal dose were 
similar compared to 3DRT. 
For the actual treatment the 9-fi eld IMRT 
plan was chosen. Treatment was well tolerated 
by the patient, who suffered from a mild skin 
reaction, dysphagia, with small changes in the 
diet and pain controlled with local analgesics. 
DISCUSSION
Medullary carcinoma is considered to be rath-
er radioresistant, but doses of 60 Gy or more 
may eradicate small residual disease [8]. Up 
to now there is not much evidence concerning 
IMRT for thyroid carcinoma. In our study more 
homogeneous dose distribution in the clinical 
target volume was achieved when IMRT was 
applied compared to 3DRT. The use of nine- or 
fi ve-fi eld IMRT produced equivalent results 
with similar dose distribution in CTVs and in 
critical structures. 5-fi eld IMRT compared to 
9-fi eld IMRT technique led to small increases 
in dose inhomogeneity, but it is suggested that 
such small differences in dose distribution are 
not clinically relevant [14].
Higher minimum and lower maximum 
dose in the target volume were delivered with 
IMRT. This is consistent with results published 
by others on thyroid carcinoma radiotherapy 
[14, 17]. In a study done by Nutting et al. [14] 
on patients diagnosed with papillary thyroid 
carcinoma, IMRT was shown to achieve bet-
ter dose distribution in the target volume, and 
reduction of the spinal cord dose when a plan 
with 5, 7 or 9 fi elds was applied, compared to 
3DRT and conventional techniques. IMRT 
was also superior in radiotherapy for naso-
pharyngeal carcinoma due to improving tar-
get coverage while sparing the organ at risk 
[10, 15, 16].
In our study, not only was better dose dis-
tribution in CTV found but also better critical 
structure sparing was achievable with IMRT 
compared with 3DRT technique. High dose 
delivered to parotid glands, larynx and spinal 
cords can lead to acute and late complications 
in patients irradiated in the head and neck re-
gion. Using 3DRT and conventional planning 
techniques we would not be able to deliver the 
prescribed dose to the target volume without 
risking complications related to irradiation of 
critical structures. In some radiotherapy pa-
tients, the dose that can be safely delivered to 
CTV has to be limited by the tolerance dose of 
the spinal cord, which is considered to be about 
46 Gy in 2 Gy per fraction. In such a situation 
a clinician must consider a compromise, by re-
ducing the target volume to the area at the high-
est risk of recurrence, which can contribute to 
failure of treatment in the lower dose region 
[14]. The biggest profi t from IMRT technique 
was gained in the parotid glands and larynx. 
In the spinal cord results obtained with IMRT 
and 3DRT were comparable. 
With improvement of treatment techniques 
we are able to deliver higher, curative doses 
to the target volume, which may improve local 
control. On the other hand, high doses could 
result in higher incidence of late side effects. 
Decrease in dose to the organ at risk may de-
crease the incidence of complications. Using 
IMRT we are able to spare the organs at risk, 
and therefore IMRT techniques open the pos-
sibility for thyroid cancer patients’ curative 
treatment even when large volumes of the 
head, neck and mediastinum have to be irra-
diated.
CONCLUSIONS
IMRT results in improved dose distribution 
within CTV compared to 3DRT. With the IMRT 
3DRT 5-fi eld- IMRT 9-fi eld- IMRT
D mean
(min / max)
D mean
(min / max)
D mean
(min / max)
CTV 60.3 
(43.9 / 66.2)
60.2 
(55.4 / 64)
59.8
(56.5 / 62,.9)
CTV2 57.6 (40.9 / 
65.7)
60.8
(58.6 / 62.4)
60.3
(58.1 / 61.8)
Larynx 61.4
(59.1 / 63.2)
54.0
(46.2 / 61.1)
54.0 
(43.1 / 60.8)
Spinal cord 27.0
(0.5 / 46.8)
27.1
(0.3 / 44.9)
28.5 
(0.4 / 44.2)
Left parotid 58.6 
(32.6 / 66.2)
46 
(5.9 / 62.3) 44.2 (5.2 / 61.9)
Right parotid 56.1 
(29.7 / 63.8)
49.7 
(18.8 / 62.6)
47.1 
(11.7 / 62.0)
Table 1. 
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plan it is also possible to reduce the dose to the 
organ at risk, especially the larynx, salivary 
glands and spinal cord. Therefore, we suggest 
that the IMRT technique should be incorpo-
rated into the practice of postoperative radio-
therapy of medullary thyroid carcinoma.
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